conference session on methods in meta analysis. The session will
include applied examples of modeling and simulation in several
therapeutic areas, and will describe research on how models based on
subject-level data and summary trial data have been used to predict
drug candidate performance, capture development knowledge, and support
the design of future clinical studies.
Additional information can be found at http://www.meduniwien.ac.at/ROeS/
"Model-based drug development continues to show value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development can benefit from the application of novel statistical methods and quantitative models to simulate expected clinical responses of new compounds, to support critical program strategies and to enhance study design decisions. Pharsight is pleased to participate at the annual ROeS Seminar, and to exchange information with industry colleagues on the strategic use of modeling and simulation."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug
development success: strong decision-making. By adopting the Pharsight
approach, customers acquire a new decision-making process with the
potential to systematically improve every level and phase of their business
and scientific processes. Phar
|SOURCE Pharsight Corporation|
Copyright©2007 PR Newswire.
All rights reserved